Results 91 to 100 of about 109,553 (260)

Treatment of Diffuse Large B Cell Lymphoma

The Korean Journal of Internal Medicine, 2012
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in all countries and all age groups. DLBCL is potentially curable, and the outcome of patients with DLBCL has completely changed with the introduction of therapy involving the monoclonal antibody rituximab in combination with chemotherapy.
openaire   +2 more sources

ICOS‐ImmunoPET Monitors T Cell Activation After Combination Immune Checkpoint Blockade in a Mouse Model of Melanoma Brain Metastasis

Advanced Science, EarlyView.
ICOS‐immunoPET noninvasively visualizes activated T cells in melanoma brain metastases following combined anti‐PD‐1/anti‐CTLA‐4 therapy. Clinical translation of this imaging approach may improve patient stratification and treatment monitoring and serve as a quantitative imaging endpoint to support immunotherapy development and clinical trials in brain ...
Renesmee C. Kuo, Rohit Verma, Sydney C. Nagy, Mausam Kalita, Samuel Aubert, Josué Ballesteros‐Álvarez, Pedro Machado Almeida, Hannes Vogel, Israt S. Alam, Michael Lim, Michelle L. James   +10 more
wiley   +1 more source

Expansion Microscopy Reveals the Spatial Association of Therapeutic Antibody–Receptor Complexes With Cholesterol‐Rich Membrane Domains

Angewandte Chemie, EarlyView.
We report a super‐resolution strategy that maps cholesterol‐rich membrane domains in whole, intact cells with an effective spatial resolution of ∼40 nm by combining expansion microscopy with a perfringolysin O domain 4 probe. This approach enables direct visualization of the spatial association between CD20 and CD38 complexes and cholesterol‐rich ...
Gang Wen, Nicole Seifert, Patrick Eiring, Johanna Meyer, Hannes Neuweiler, Julia Weingart, Ignacio Vega‐Vásquez, Sören Doose, Philip Kollmannsberger, Markus Sauer   +9 more
wiley   +2 more sources

Engineering Antibodies into Targeted Chimeras: From Recognition Modules to Programmable Degraders

Advanced Science, EarlyView.
Antibody can be engineered into diverse lysosome‐targeting chimeras that convert target recognition into active degradation. By coupling antibody binding with recruited receptors, encoded domains, conjugated ligands, or nanoparticle scaffolds, these antibody‐associated targeted chimeras (AbTACs) platforms direct extracellular and membrane proteins ...
Kaige Chen, Quanyin Hu
wiley   +1 more source

Diagnosis and treatment of diffuse large B-cell lymphoma

Swiss Medical Weekly, 2012
Diffuse large B-cell lymphoma (DLBCL) is the most frequently-occurring type of malignant lymphoma in the Western world. It has an aggressive natural history, with a median survival of less than one year if left untreated. Immunochemotherapy regimens, consisting of the anti-CD20 antibody rituximab typically in combination with cyclophosphamide ...
Mey, U, Hitz, F, Lohri, A, Pederiva, S, Taverna, C, Tzankov, A, Meier, O, Yeow, K, Renner, C   +8 more
openaire   +3 more sources

EBV‐Driven ODC1 Upregulation Enhances Polyamine Anabolism to Promote Viral Replication and Cisplatin Resistance in Nasopharyngeal Carcinoma

Advanced Science, EarlyView.
EBV‑BZLF1 initiates ODC1‑driven polyamine anabolism that correlates with poor clinical prognosis in nasopharyngeal carcinoma. The ODC1–spermidine axis promotes viral replication, cell proliferation and innate immune evasion. Pharmacological inhibition of ODC1 rescues cisplatin sensitivity, establishing ODC1 as a viable therapeutic target for EBV ...
Yueshuo Li, Xudong Hu, Chenxing Yang, Na Liu, Lin Wang, Xi Cai, Min Tang, Ya Cao, Li Shang, Feng Shi   +9 more
wiley   +1 more source

Spontaneous resolution of untreated diffuse large B‐cell lymphoma of maxillary bone after incisional biopsy

Clinical Case Reports, 2019
Diffuse large B‐cell lymphoma (DLBCL) is a heterogeneous group of lymphomas which require multiagent therapy for remission induction and are associated with relapse in more than 40% of patients.
Lainey Flatow‐Trujillo, Khine Win, Amy Jencks, Leslie Andritsos, Cecilia Arana Yi   +4 more
doaj   +1 more source

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

Haematologica, 2017
Activation of the phosphatidylinositol 3-kinase/mechanistic target of rapamycin pathway plays a role in the pathogenesis of non-Hodgkin lymphoma. This multicenter, open-label phase 2 study evaluated buparlisib (BKM120), a pan-class I phosphatidylinositol
Anas Younes, Gilles Salles, Giovanni Martinelli, Robert Gregory Bociek, Dolores Caballero Barrigon, Eva González Barca, Mehmet Turgut, John Gerecitano, Oliver Kong, Chaitali Babanrao Pisal, Ranjana Tavorath, Won Seog Kim   +11 more
doaj   +1 more source

SynNotch Receptors for Visualizing Immunoreceptor Force Transmission and Downstream Signaling In Vivo

Advanced Science, EarlyView.
A mechanically activated SynNotch reporter platform enables detection of force transmission through receptors as they mediate immune cell interactions. Targeting CD40 on B cells and TCR on T cells records force‐induced reporter activation across 2D coculture, 3D organoid, and implanted in mice, which also reveal force‐amplification of immune receptor ...
Menglan Li, Jintian Lyu, Kaitao Li, Ameya Dravid, Deepali Balasubramani, Amir H. K. Ashkezari, Hyun‐Kyu Choi, Gabriel A. Kwong, Ankur Singh, Cheng Zhu   +9 more
wiley   +1 more source

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang, Zhicheng Zhou, Xue Jiang, Zhenguang Du, Yangyang Zhan, Xinli Liu   +5 more
wiley   +1 more source